Login
Werewolf Therapeutics, Inc. logo

Werewolf Therapeutics, Inc.

werewolftx.com

What Do They Do?

Develops conditionally activated immune therapies for cancer and other immune-mediated conditions, including cytokine medicines and immune cell engagers for cancer.

Who Are Their Customers?

Jazz Pharmaceuticals Ireland Limited holds worldwide rights to develop and commercialize JZP898 under a collaboration and license agreement.

How Are They Changing?

Since the FY2025 annual report
  • Aug 21, 2026 Agreed to merge with Ambros Therapeutics The proposed combined company would focus on Ambros Therapeutics’ neridronate development program.
  • Aug 14, 2026 Sold preclinical platform assets to EMD Serono The sale covered the preclinical INDUCER platform and parts of INDUKINE; Werewolf retained rights to continue WTX-124 and WTX-330.

Added immune cell engagers The latest report describes conditionally activated immune cell engagers alongside its INDUKINE cytokine medicines; the older report described its platform and pipeline mainly through INDUKINE molecules and other immune-oncology discovery programs.

Who Do They Compete With?

Competes with Anaveon, Anwita Biosciences, Ascendis Pharma, Asher Biotherapeutics, Aulos Bioscience, BioNTech, Cue Biopharma, DEKA Biosciences, Merck &, Medicenna Therapeutics, F. Hoffmann-La Roche, Synthekine, Xilio Therapeutics, Sanofi, DragonFly Therapeutics, Juno Therapeutics, OncoSec Medical, PDS Biotechnology, Philogen, and Sonnet BioTherapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support